Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis

Abstract

Background:

Brain atrophy is a known marker of irreversible tissue damage in multiple sclerosis (MS). Cerebrospinal fluid (CSF) osteopontin (OPN) and neurofilament light chain (NF-L) have been proposed as candidate surrogate markers of inflammatory and neurodegenerative processes in MS.

Objective:

To evaluate the relationship between CSF NF-L and OPN levels and brain grey and white matter volumes in patients with clinically isolated syndrome (CIS) suggestive of MS.

Methods:

A total of 41 CIS patients and 30 neurological controls (NCs) were included. CSF NF-L and OPN were measured by commercial ELISA. Measures of brain volume (normalized brain volume (NBV), normalized grey matter volume (NGV), peripheral grey matter volume (PGV), normalized white matter volume (WMV), and ventricular volume) were obtained by SIENAX. Corpus callosum index (CCI) was calculated. Brain volumes were categorized into ‘high’ and ‘low’ according to the median value.

Results:

CSF NF-L and OPN levels were higher in CIS patients in comparison with NCs. CIS patients with ‘low’ TGV, PGV, and TBV showed higher CSF NF-L levels than CIS patients with ‘high’ brain volumes. TGV and PGV correlated inversely with NF-L levels, whereas CCI was inversely related to OPN levels. CSF NF-L was the only independent predictor of TGV and PGV.

Conclusion:

CSF NF-L tracks mainly grey matter damage in patients with CIS suggestive of MS.

Keywords

Clinically isolated syndromes brain volume neurofilament osteopontin

Get full access to this article

View all access options for this article.

References

De Stefano

Matthews

Filippi

. Evidence of early cortical atrophy in MS: Relevance to white matter changes and disability. Neurology 2003; 60: 1157–1162.

Dalton

Chard

Davies

. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127: 1101–1107.

Calabrese

Rinaldi

Mattisi

. The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011; 77: 257–263.

Pérez-Miralles

Sastre-Garriga

Tintoré

. Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler 2013; 19: 1878–1886.

Roosendaal

Bendfeldt

Vrenken

. Grey matter volume in a large cohort of MS patients: Relation to MRI parameters and disability. Mult Scler 2011; 17: 1098–1106.

Uher

Benedict

Horakova

. Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. J Neurol Sci 2014; 347: 229–234.

Filippi

Preziosa

Copetti

. Gray matter damage predicts the accumulation of disability 13 years later in MS. Neurology 2013; 81: 1759–1767.

Chowdhury

Lin

Sadiq

SA.

Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Arch Neurol 2008; 65: 232–235.

Bornsen

Khademi

Olsson

. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler 2010; 17: 32–42.

10.

Ashkar

Weber

Panoutsakopoulou

. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860–864.

11.

Kuhle

Leppert

Petzold

. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011; 76: 1206–1213.

12.

Fialova

Bartos

Svarcova

. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolate syndrome suggestive of multiple sclerosis. J Neuroimmunol 2013; 262: 113–120.

13.

Khalil

Enzinger

LangKammer

. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler 2013; 19(4): 436–442.

14.

Tortorella

Direnzo

Taurisano

. Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. Mult Scler 2015; 21: 396–401.

15.

Mañé Martínez

Olsson

Bau

. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler 2015; 21: 550–561.

16.

Gunnarsson

Malmestrom

Axelsson

. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83–89.

17.

Kuhle

Disanto

Lorscheider

. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015; 84: 1639–1643.

18.

Iaffaldano

Ruggieri

Viterbo

. The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. Brain Behav Immun 2014; 35: 176–181.

19.

Eikelenboom

Petzold

Lazeron

RHC

. Multiple Sclerosis: Neurofilament Light Chain antibodies are correlated to cerebral atrophy. Neurology 2003; 60: 219–223.

20.

Polman

Reingold

Edan

. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol 2005(58): 840–846.

21.

Kurtzke

JF.

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.

22.

Polman

Reingold

SDC

Banwell

. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.

23.

Smith

Zhang

Jenkinson

. Accurate, robust and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479–489.2002.

24.

Figueira

Santos

Silva

. Corpus callosum index: A practical measure for long term follow-up in multiple sclerosis. Arq Neuropsiquiatr 2007; 65: 931–935.

25.

Figueira

Santos

Silva

FC.

A cognitive imaging correlate in multiple sclerosis. Rev Chil Neuropsiquiatr 2003; 41: 86–87.

26.

Witelson

SF.

Hand and sex differences in the isthmus and genu of the human corpus callosum: A postmortem morphological study. Brain 1989; 112: 799–835.

27.

Hofer

Frahma

Topography of the human corpus callosum revisited: Comprehensive fiber tractography using diffusion tensor magnetic resonance imaging. Neuroimage 2006; 32: 989–994.

28.

Granberg

Bergendal

Shams

. MRI-defined corpus callosal atrophy in Multiple Sclerosis: A comparison of volumetric measurements, corpus callosum area and index. J Neuroimaging 2015; 25(6): 996–1001.

29.

Arrambide

Espejo

Eixarch

. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology 2016; 87: 1076–1084.

30.

Scherling

Hall

Berisha

. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 2014; 75: 116–126.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.22 MB